ST 101

Drug Profile

ST 101

Alternative Names: ST101; ZSET-1446

Latest Information Update: 22 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zenyaku Kogyo
  • Developer Sonexa Therapeutics
  • Class Antidementias; Indans; Nootropics; Small molecules; Spiro compounds
  • Mechanism of Action Acetylcholine stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Essential tremor

Most Recent Events

  • 22 Jul 2015 Discontinued - Phase-II for Alzheimer's disease in USA and Canada (PO)
  • 22 Jul 2015 Discontinued - Phase-II for Essential tremor in USA (PO)
  • 06 May 2011 Phase-II clinical trials in Essential tremor in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top